- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04104919
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of Brivoligide Injection in Patients With a Pain Catastrophizing Scale Score ≥16 Undergoing Mastectomy With Immediate Tissue Expander or Implant Placement
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Potential subjects will be prescreened for PCS score; pre-qualified patients will be invited to the investigative site for informed consent and full screening within 30 days of randomization. Patients providing informed consent and meeting all study eligibility criteria will be enrolled in the study on the day of surgery (Day 1).
Subjects will receive study drug just prior to anesthesia induction. Study assessments will be entered by subjects in the electronic diary from Day 1 through Day 21. Follow-up visits will occur on Days 7 and 21 (± 2 days).
Type d'étude
Phase
- Phase 2
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Score of 16 or greater on the PCS scale
- Scheduled to undergo unilateral or bilateral mastectomy with immediate tissue expander or implant placement
- American Society of Anesthesiologists Physical Status Classification System ≤ 3
- Medically stable for this surgery with general anesthesia and intrathecal administration of study drug as determined by the Investigator
- Body mass index of 18-45 kg/m2
- Have a stable medical regimen (for prescribed medications) for ≥ 7 days before randomization
- Able to read and understand study instructions in English or Spanish, and willing and able to comply with all study procedures
Exclusion Criteria:
- Prior breast surgery in the index breast (either breast for bilateral surgery) in the last two years, other than biopsies and small/moderate volume lumpectomies
- Induction chemotherapy or plans for adjunctive chemotherapy or any radiotherapy within 21 days of surgery
- Known spinal deformities or cutaneous infection in the lumbar area that would preclude intrathecal administration of study drug
- Planned use of liposomal formulated or long-acting local anesthetics, extended release opioid formulations (e.g., Oxycontin), long half-life opioids (e.g., methadone), or drugs with potential for adverse cognitive or memory effects (e.g., ketamine, scopolamine, or propranolol) preoperatively and/or at any time through the duration of the study
- Use of more than 40 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization
- Current neurologic disorder, which could confound the assessment of pain
- Unstable mental condition which would prevent the patient from understanding the nature and scope of the study and/or evidence of an uncooperative attitude in the opinion of the Investigator
- Women who are pregnant or nursing
- Participation in a clinical trial with the last dose or intervention within 1 month of randomization, or planned treatment in a clinical trial during this study
- Previous participation in any study involving brivoligide injection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Brivoligide Injection 660 mg/6 mL
Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher.
After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
|
Injection intrathécale préopératoire unique
Autres noms:
|
Comparateur placebo: Placebo 6 mL
Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher.
After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
|
Injection intrathécale préopératoire unique
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pain with general movement involving the chest and upper body
Délai: Day 3 to Day 14
|
Least Squares (LS) Mean pain rating with general movement involving the chest and upper body on the 0 - 10 Numerical Rating Scale (0 = No Pain; 10 = Worst Pain)
|
Day 3 to Day 14
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pain at rest
Délai: Day 3 to Day 14
|
Least Squares (LS) Mean pain rating at rest on the 0 - 10 Numerical Rating Scale (0 = No Pain; 10 = Worst Pain)
|
Day 3 to Day 14
|
Pain with deep full inspiration and forceful effective cough
Délai: Day 3 to Day 14
|
Least Squares (LS) Mean pain rating with deep full inspiration and forceful effective cough on the 0 - 10 Numerical Rating Scale (0 = No Pain; 10 = Worst Pain)
|
Day 3 to Day 14
|
Pain with ipsilateral arm abduction
Délai: Day 14 to Day 21
|
Least Squares (LS) Mean pain rating with ipsilateral arm abduction on the 0 - 10 Numerical Rating Scale (0 = No Pain; 10 = Worst Pain)
|
Day 14 to Day 21
|
Total use of postoperative opioid medications
Délai: Day 3 to Day 14
|
Total use (median) of postoperative opioid medications (morphine equivalents)
|
Day 3 to Day 14
|
Total use of postoperative opioid medications
Délai: Day 1 through Day 21
|
Total use (median) of postoperative opioid medications (morphine equivalents)
|
Day 1 through Day 21
|
Change from baseline for the BREAST-Q
Délai: Screening to Day 21
|
Change from baseline to Day 21 for the BREAST-Q
|
Screening to Day 21
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ADYX-006
- 1UG3DA048375-01 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Douleur, Postopératoire
-
Evergrain, LLCINQUIS Clinical Research Ltd.ComplétéSatiété du pain riche en fibres et riche en protéinesCanada
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceComplétéChangements de poids corporel | Modification alimentaire | Microbiote gastro-intestinal | Pain | Tests hématologiquesIsraël
-
University of BergenUniversity of Leipzig; Chalmers University of Technology; Nofima; Paderborn UniversityComplétéHyperglycémie | Prédiabète | Contrôle glycémique | PainNorvège
-
Ege UniversityComplétéObésité | Index glycémique | Glucose sanguin | PainTurquie
Essais cliniques sur Brivoligide injectable 660 mg/6 mL
-
Adynxx, Inc.Retiré
-
NPO PetrovaxComplétéInfection respiratoire aiguëFédération Russe
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Complété
-
Vista KlinikPas encore de recrutementŒdème maculaire diabétique
-
Leonardo ClavijoAmgenInconnueMaladie artérielle périphériqueÉtats-Unis
-
Azza Mohamed Ahmed SaidAin Shams UniversityInconnue
-
Advanz PharmaAstellas Pharma US, Inc.ComplétéFlutter auriculaireÉtats-Unis, Canada, Danemark, Suède
-
Advanz PharmaAstellas Pharma US, Inc.ComplétéFibrillation auriculaireÉtats-Unis, Canada, Suède, Danemark
-
MiMedx Group, Inc.Résilié
-
Suzhou Connect Biopharmaceuticals, Ltd.ComplétéSujets adultes en bonne santéChine